Expression of a mutant prohibitin from the aP2 gene promoter leads to obesity-linked tumor development in insulin resistance-dependent manner

Oncogene

Volumn 35, Issue 34, 2016, Pages 4459-4470

  Ande, S R ^a   Nguyen, K H ^a   Padilla Meier, G P ^a   Nyomba, B L G ^a   Mishra, S ^a  

^a UNIVERSITY OF MANITOBA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; CCL28 CHEMOKINE; CHEMERIN; COMPLEMENT COMPONENT C5; COMPLEMENT COMPONENT C5A; CUTANEOUS T CELL ATTRACTING CHEMOKINE; CXCL13 CHEMOKINE; CXCL16 CHEMOKINE; EOTAXIN; FRACTALKINE; GAMMA INTERFERON; GHRELIN; GLUCOSE; GRANULOCYTE CHEMOTACTIC PROTEIN 2; INSULIN; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 15; INTERLEUKIN 16; INTERLEUKIN 18; INTERLEUKIN 2; INTERLEUKIN 6; LEPTIN; MITOGEN ACTIVATED PROTEIN KINASE 1; PROHIBITIN; PROTEIN KINASE B; RESISTIN; SECONDARY LYMPHOID TISSUE CHEMOKINE; STROMAL CELL DERIVED FACTOR 1; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; ADIPOCYTOKINE; CHEMOKINE; CYTOKINE; FABP4 PROTEIN, MOUSE; FATTY ACID BINDING PROTEIN; REPRESSOR PROTEIN;

ADIPOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARCINOGENESIS; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GENETIC ASSOCIATION; GLUCOSE HOMEOSTASIS; GLUCOSE INTOLERANCE; HYPERINSULINEMIA; IMMUNE RESPONSE; INSULIN RESISTANCE; LYMPHADENOPATHY; MALE; METABOLIC DISORDER; METABOLIC REGULATION; MOUSE; MUTANT; NEOPLASM; NONHUMAN; OBESITY; OVARIECTOMY; PRIORITY JOURNAL; PROMOTER REGION; SEX DIFFERENCE; SIGNAL TRANSDUCTION; SINUS HISTIOCYTOSIS; TRANSGENIC MOUSE; ANIMAL; BLOOD; CELL CULTURE; COMPLICATION; GENETICS; HISTIOCYTOSIS; HYPERINSULINISM; MUTATION; NEOPLASMS; PHYSIOLOGY; SEXUAL DEVELOPMENT;

ADIPOKINES; ANIMALS; CELLS, CULTURED; CHEMOKINES; CYTOKINES; FATTY ACID-BINDING PROTEINS; FEMALE; HISTIOCYTOSIS; HYPERINSULINISM; INSULIN RESISTANCE; LYMPHADENOPATHY; MALE; MICE; MUTATION; NEOPLASMS; OBESITY; PROMOTER REGIONS, GENETIC; REPRESSOR PROTEINS; SEX CHARACTERISTICS;

EID: 84954502433     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2015.501     Document Type: Article

References (48)

1. Ng M, Fleming T, Robinson M, Thomson B, Graetz N, Margono C et al. Global, regional, and national prevalence of overweight and obesity in children and adults during 1980-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 2014; 384: 766-781.
2. Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet 2008; 371: 569-578.
3. Wolin KY, Carson K, Colditz GA. Obesity and cancer. Oncologist 2010; 5: 556-565.
4. Makarem N, Lin Y, Bandera EV, Jacques PF, Parekh N. Concordance with World Cancer Research Fund/American Institute of for Cancer Research (WCRF/AICR) guidelines for cancer prevention and obesity-related cancer risk in the Framingham Offspring cohort (1991-2008). Cancer Causes Control 2015; 26: 277-286.
5. Hernandez BY, Wilkens LR, LeMarchand L, Horio D, Chong CD, Loo LW. Difference in IGF-axis protein expression and survival among multiethnic breast cancer patients. Cancer Med 2015; 4: 354-362.
6. Madeddu C, Gramigano G, Floris C, Muenu G, Sollari G, Maccio A. Role of inflammation and oxidative stress in post-menopausal estrogen-dependent breast cancer. J Cell Mol Med 2014; 18: 2519-2529.
7. Rose DP, Komninou D, Stephenson GD. Obesity, adipocytokines, and insulin resistance in breast cancer. Obes Rev 2004; 5: 153-165.
8. DeCensi A, Puntoni M, Gandini S, Guerrieri-Gonzaga A, Johansson HA, Cazzaniga M et al. Differential effects of metformin on breast cancer proliferation according to markers of insulin resistance and tumor subtype in a randomized presurgical trial. Breast Cancer Res Treat 2014; 148: 81-90.
9. Zhao M, Ramaswamy B. Mechanisms and therapeutic advances in the management of endocrine-resistant breast cancer. World J Clin Oncol 2014; 5: 248-262.
10. Renehan AG, Frystyk J, Flyvbjerg A. Obesity and cancer risk: the role of the insulin- IGF axis. Trends Endocrinol Metab 2006; 17: 328-336.
11. Gallagher EJ, Alikhani N, Tobin-Hess A, Blank J, Buffin NJ, Zelenko Z et al. Insulin receptor phosphorylation by endogenous insulin or the insulin analog AspB10 promotes mammary tumor growth independent of IGF-I receptor. Diabetes 2013; 62: 3553-3560.
12. Gahete MD, Córdoba-Chacón J, Lantvit DD, Ortega-Salas R, Sanchez-Sanchez R, Pérez-Jiménez F et al. Elevated GH/IGF-I promotes mammary tumors in high-fat, but not low-fat, fed mice. Carcinogenesis 2014; 35: 2467-2473.
13. Hvid H, Blouin MJ, Birman E, Damgaard J, Poulsen F, Fels JJ et al. Treatment with insulin analog X10 and IGF-1 increases growth of colon cancer allografts. PLoS One 2013; 8: e79710.
14. Nakagawa H, Umemura A, Taniguchi K, Font-Burgada J, Dhar D, Ogata H et al. ER stress cooperates with hypernutrition to trigger TNF-dependent spontaneous HCC development. Cancer Cell 2014; 26: 331-343.
15. Zhang Y, Daquinag A, Traktuev DO, Amaya-Manzanares F, Simmons PJ, March KL et al. White adipose tissue cells are recruited by experimental tumors and promote cancer progression in mouse models. Cancer Res 2009; 69: 5259-5266.
16. Cleary MP. Impact of obesity on development of mammary tumors in preclinical models of breast cancer. J Mammary Gland Biol Neoplasia 2013; 18: 333-343.
17. Ande SR, Gu Y, Nyomba BL, Mishra S. Insulin induced phosphorylation of prohibitin at tyrosine 114 recruits Shp1. Biochim Biophys Acta 2009; 1793: 1372-1378.
18. Ande SR, Xu Z, Gu Y, Mishra S. Prohibitin has an important role in adipocyte differentiation. Int J Obes (Lond) 2012; 36: 1236-1244.
19. Ande SR, Nguyen KH, Padilla-Meier GP, Wahida W, Nyomba BLG, Mishra S. Prohibitin overexpression in adipocytes induces mitochondrial biogenesis, leads to obesity development, and affects glucose homeostasis in a sexspecific manner. Diabetes 2014; 63: 3734-3741.
20. Nijtmans LG, Artal SM, Grivell LA, Coates PJ. The mitochondrial PHB complex: roles in mitochondrial respiratory complex assembly, ageing and degenerative disease. Cell Mol Life Sci 2002; 59: 143-155.
21. Sharma A, Qadri A. Vi polysaccharide of Salmonella typhi targets the prohibitin family of molecules in intestinal epithelial cells and suppresses early inflammatory responses. Proc Natl Acad Sci USA 2004; 101: 17492-17497.
22. Richter-Dennerlein R, Korwitz A, Haag M, Tatsuta T, Dargazanli S, Baker M et al. DNAJC19, a mitochondrial cochaperone associated with cardiomyopathy, forms a complex with prohibitins to regulate cardiolipin remodeling. Cell Metab 2014; 20: 158-171.
23. Kim DK, Kim HS, Kim A-R, Jang GH, Kim HW, Park YH et al. The scaffold protein prohibitin is required for antigen-stimulated signaling in mast cells. Sci Signal 2013; 6: 292.
24. Rajalingam K, Wunder C, Brinkmann V, Churin Y, Hekman M, Sievers C et al. Prohibitin is required for Ras-induced Raf-MEK-ERK activation and epithelial cell migration. Nat Cell Biol 2005; 8: 873-843.
25. Fu Y, Luo L, Luo N, Garvey WT. Lipid metabolism mediated by adipocyte lipid binding protein (ALBP/aP2) gene expression in human THP-1 macrophages. Atherosclerosis 2006; 188: 102-111.
26. Kusminski CM, Holland WL, Sun K et al. MitoNEET-driven alterations in adipocyte mitochondrial activity reveal a crucial adaptive process that preserves insulin sensitivity in obesity. Nat Med 2012; 18: 1539-1549.
27. Roding S, Chan JKC. Tumors of the lymphoreticular system, including spleen and thymus. Part A Lymph node. Chapter 21. In: Fletcher CDM (ed), Diagnostic Histopathology of Tumors, 4th edn. Elsevier: Philadelphia, PA, USA, 2013.
28. Terashima M, Kim KM, Adachi T, Nielsen PJ, Reth M, Köhler G et al. The IgM receptor of B lymphocytes is associated with prohibitin and a prohibitin-related protein. EMBO J 1994; 13: 3782-3792.
29. Rutkowski MR, Stephen TL, Svoronos N, Allegrezza MJ, Tesone AJ, Perales-Puchalt A et al. Microbially driven TLR5-dependent signaling governs distal malignant progression through tumor-promoting inflammation. Cancer Cell 2015; 27: 27-40.
30. Schipper HS, Prakken B, Kalkhoven E, Boes M. Adipose tissue-resident immune cells: key players in immunometabolism. Trends Endocrinol Metab 2012; 23: 407-415.
31. Venkan K, Seeuws S, Zabeau L, Jacques P, Decruy T, Coudenys J et al. A bidirectional crosstalk iNKT cells and adipocytes mediated by leptin modulates susceptibility for T cell mediated hepatitis. J Hepatol 2013; 60: 175-182.
32. Ande SR, Mishra S. Prohibitin interacts with phosphatidylinositol 3, 4, 5-triphosphate (PIP3) and modulates insulin signaling. Biochem Biophys Res Commun 2009; 390: 1023-1028.
33. Markle JG, Fish EN. SeXX matters in immunity. Trends Immunol 2014; 35: 97-104.
34. Dixit VD. Adipose-immune interactions during obesity and caloric restriction: reciprocal mechanisms regulating immunity and health span. J Leukoc Biol 2008; 84: 882-892.
35. Dixit VD, Schaffer EM, Pyle RS, Collins GD, Sakthivel SK, Palaniappan R et al. Ghrelin inhibits leptin- and activation-induced proinflammatory cytokine expression by human monocytes and T cells. J Clin Invest 2004; 114: 57-66.
36. Mathis D, Shoelson S. Immunometabolism: an emerging frontier. Nat Rev Immunol 2011; 11: 81-83.
37. Sell H, Habich C, Eckel J. Adaptive immunity in obesity and insulin resistance. Nat Rev Endocrinol 2012; 8: 709-716.
38. Leenen PJM, Bechan GI, Melis M, den Broeder BJH, Lohler J, Egeler RM.Heterogeneity in a mouse model of histiocytosis: transformation of Langerin+ dendritic cells, macrophages, and precursors. J Leukoc Biol 2010; 87: 949-958.
39. Nikolic T, Leenen PJM. Histiocyte function and development in the normal immune system. In: Weitzman S, Egeler RM (eds). Histiocytic Disorders of Children and Adults. Cambridge University Press: Cambridge, UK, 2005, pp 40-65.
40. Pileri SA, Grogan TM, Harris NL, Banks P, Campo E, Chan JK et al. Tumours of histiocytes and accessory dendritic cells: an immunohistochemical approach to classification from the International Lymphoma Study Group based on 61 cases. Histopathology 2002; 41: 1-29.
41. De Gruijl TD, Sombroek CC, Lougheed SM, Oosterhoff D, Buter J, van den Eertwegh AJ et al. A postmigrational switch among skin-derived dendritic cells to a macrophage-like phenotype is predetermined by the intracutaneous cytokine balance. J Immunol 2006; 176: 7232-7242.
42. Dixit VD, Cooper-Jenkins A, Taub DD. T cell derived ghrelin is required for regulation of NF-kB and T-helper 1 cytokines. Brain Behav Immun 2006; 20: 14.
43. Gonzalez-Rey E, Chorny A, Delgado M. Therapeutic action of ghrelin in a mouse model of colitis. Gastroenterology 2006; 130: 1707-1720.
44. Li WG, Gavrila D, Liu X, Wang L, Gunnlaugsson S, Stoll LL et al. Ghrelin inhibits proinflammatory responses and nuclear factor-kB activation in human endothelial cells. Circulation 2004; 109: 2221-2226.
45. Wiedmer P, Nogueiras R, Broglio F, D'Alessio D, Tschöp MH. Ghrelin, obesity and diabetes. Nat Clin Pract Endocrinol Metab 2007; 3: 705-712.
46. Takahashi S, Masuda J, Shimagami H, Ohta Y, Kanda T, Saito K et al. Mild caloric restriction up-regulates the expression of prohibitin: a proteome study. Biochem Biophy Res Commun 2011; 405: 462-467.
47. Artal-Sanz M, Tavernarakis N. Prohibitin couples diapause signalling to mitochondrial metabolism during ageing in C. elegans. Nature 2009; 461: 793-797.
48. Haabeth OAW, Lorvik KB, Hammarstrom C, Donaldson IM, Haraldsen G, Bogen B et al. Inflammation driven by tumor-specific Th1 cells protects against B-cell cancer. Nat Commun 2011; 2: 240.